Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Basilea Pharmaceutica Deutschland GmbH, Marie-Curie-Strasse 8, 79539, Lörrach, Germany
CRESEMBA 200 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. White to yellow powder. |
Each vial contains 200 mg isavuconazole (as 372.6 mg isavuconazonium sulfate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Isavuconazole |
Isavuconazole is an active form of isavuconazonium. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis. |
| List of Excipients |
|---|
|
Mannitol |
One 10 mL Type I glass vial with rubber stopper and an aluminum cap with plastic seal.
Basilea Pharmaceutica Deutschland GmbH, Marie-Curie-Strasse 8, 79539, Lörrach, Germany
EU/1/15/1036/001
Date of first authorisation: 15 October 2015
| Drug | Countries | |
|---|---|---|
| CRESEMBA | Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
